CurrentCentenePolicy CP.MP.141

Non-Myeloablative Allogeneic Stem Cell Transplants

This policy provides clinical guidance and medical necessity criteria for non-myeloablative (reduced-intensity) allogeneic hematopoietic stem cell transplantation and is intended for providers, members/enrollees, and administrators applying Centene coverage determinations.

Policy Summary

PayerCentene

PolicyNon-Myeloablative Allogeneic Stem Cell Transplants

Policy CodePolicy CP.MP.141

Change TypeNo material change

Effective Date

Next Review Date

Key ActionConsult applicable coverage documents and regulatory requirements when using this medical necessity guide to support prior authorization decisions.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

refs 18-36peer-reviewed and guideline citations listed

state precedenceMedicaid and Medicare guidance precedence

Centenepolicy ownership

Coverage Criteria Summary

Coverage under this policy is subject to the specific terms, conditions, exclusions, and limitations of the member’s coverage documents and contract. Providers, members/enrollees, and their representatives are bound by those contract terms and by the policy when providing services or submitting claims for payment.

For members/enrollees covered by Medicaid, state Medicaid coverage provisions take precedence where they conflict with this clinical policy; consult the applicable state Medicaid manual for details. For Medicare members/enrollees, review all applicable Medicare National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Medicare Coverage Articles prior to applying the criteria in this policy.

Provider Guidance and Administrative Notes

Prior Authorization

Prior Authorization / Medical Necessity Guidance

This policy is intended to guide coverage determinations and clinical review. Providers should consult member-specific benefits, plan documents, and payer rules when submitting requests. Prior authorization may be required for services described in this policy; always verify authorization requirements and obtain approvals before rendering non-emergent services.

Check member eligibility and benefits before scheduling services.
Obtain prior authorization when required by the member's plan.

Policy Summary

PayerCentene

PolicyNon-Myeloablative Allogeneic Stem Cell Transplants

Policy CodePolicy CP.MP.141

Change TypeNo material change

Effective Date

Next Review Date

Key ActionConsult applicable coverage documents and regulatory requirements when using this medical necessity guide to support prior authorization decisions.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Include clinical documentation supporting medical necessity with the authorization request.

Note

Coverage Documents and Regulatory Precedence

Coverage decisions are governed first by the member's coverage documents. For Medicaid members, state Medicaid coverage provisions and manuals take precedence over this policy when conflicts exist. For Medicare members, applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Medicare Coverage Articles must be reviewed and followed.

Medicaid: Follow state Medicaid manuals where they conflict with this policy.
Medicare: Review relevant NCDs, LCDs, and CMS guidance at http://www.cms.gov prior to applying policy criteria.

Denial Risk

Contractual Binding and Claim Submission

Providers, members/enrollees and their representatives are bound by the terms and conditions of their contracts with the payer. Submission of a claim or provision of services constitutes agreement to these terms. Claims not meeting contractual requirements or lacking required authorizations/documentation may be denied or subject to retrospective review.

Providers agree to contract terms by submitting claims or providing services.
Failure to secure required authorization or documentation may result in claim denials or recoupment.

Documentation Required

Providers must follow any additional administrative requirements specified by the payer (e.g., referral procedures, timely filing limits, billing/coding rules). Ensure that documentation supports the level of service billed and that any required pre-service or concurrent reviews are completed.

Adhere to referral, timely filing, and billing rules in provider contract and payer policies.
Maintain clinical records sufficient to demonstrate medical necessity and support submitted codes.

Clinical Evaluation and Eligibility Requirements

Documentation Required

Evaluation — review and document applicable guidelines and literature

Review of current clinical guidelines and literature (e.g., NCCN, UpToDate, cited reviews) is referenced as the clinical basis for determining eligibility and evaluation for non‑myeloablative allogeneic hematopoietic cell transplantation; documentation should support that guideline-based considerations were reviewed.

Document which guidelines and literature (NCCN, UpToDate, cited studies) were considered in the evaluation.
Provide clinical rationale in the record showing applicability of guideline-supported indications for the member.

Facility and Provider Experience Expectations

Step Therapy

Center and provider qualifications — ensure experienced, licensed team and capabilities

Care should be provided by appropriately experienced and licensed health care professionals at transplant centers with capabilities to perform allogeneic hematopoietic cell transplantation; the policy references standard expectations but does not specify accreditation or volume thresholds.

Ensure clinicians and the transplant program have documented experience and licensure appropriate for allogeneic HSCT.
Maintain documentation of center capabilities and team qualifications in the medical record.

Background and Evidence Summary

This policy’s clinical basis is supported by contemporary guideline and literature sources, including National Comprehensive Cancer Network (NCCN) guidelines and transplant-focused reviews that address indications for allogeneic hematopoietic cell transplantation and conditioning approaches.

Evidence and guidance cited in the source document include peer-reviewed transplant literature and specialty society guidance discussing non‑myeloablative / reduced‑intensity conditioning regimens—approaches developed to reduce toxicity for older or medically frail patients while preserving graft-versus-tumor effects. Review of these references and relevant UpToDate topics provides the clinical context for eligibility and evaluation considerations referenced in this policy.

Policy ownership and copyright are held by Centene Corporation; users should follow the referenced guidance and applicable regulatory requirements when applying the clinical recommendations in this document.

Key Definitions

Non-myeloablative / Reduced-intensity conditioning — definition and intent

DefinitionConditioning regimens with lower dose intensity used prior to allogeneic hematopoietic cell transplantation intended to reduce toxicity for older or medically frail patients while preserving graft-versus-tumor effects.

Clinical intentReduce regimen-related toxicity and transplant-related mortality in patients who are older or have significant comorbidities compared with myeloablative conditioning.

Typical patient populationOlder adults (examples reported in literature: patients aged 60–78 years) and medically frail individuals who may not tolerate myeloablative conditioning.

Supporting evidenceContemporary reviews and studies (e.g., Storb & Sandmaier 2016; Samuelson et al. 2011) and dose-intensity analyses discuss indications and outcomes for reduced-intensity approaches.

Common regimen components (examples cited)Fludarabine-based reduced-intensity regimens are reported in the literature as part of non-myeloablative approaches.